Get the Stockscreener App
6.4164
5.79%
0.3664
Verve Therapeutics Inc stock is traded at $6.4164, with a volume of 922.94K.
It is up +5.79% in the last 24 hours and up +28.00% over the past month.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$6.05
Open:
$6.19
24h Volume:
922.94K
Relative Volume:
0.70
Market Cap:
$511.98M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-2.0241
EPS:
-3.17
Net Cash Flow:
$-134.39M
1W Performance:
+6.84%
1M Performance:
+28.00%
6M Performance:
-0.16%
1Y Performance:
-58.92%
1-Day Range:
$6.135
$6.77
1-Week Range:
$5.62
$6.77
52-Week Range:
$4.305
$20.12
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Verve Therapeutics reports Q3 EPS (59c), consensus (70c) - TipRanks
Verve Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vanguard Group Inc's Strategic Reduction in Verve Therapeutics I - GuruFocus.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com
Deadline coming up on Oct. 28th in Lawsuit for Investors who lost - openPR
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - AccessWire
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AccessWire
FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - PR Newswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - cnhinews.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - PR Newswire
VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - GlobeNewswire Inc.
SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7%Still a Buy? - MarketBeat
Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion - ForexTV.com
Verve Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback - MSN
Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – VERV - ForexTV.com
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - AccessWire
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. - The Bakersfield Californian
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - AccessWire
Investors who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - AccessWire
2024-10-21 | Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV | NDAQ:VERV | Press Release - Stockhouse Publishing
VERV Deadline: VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: - GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. LawsuitVERV - AccessWire
2024-10-21 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. LawsuitVERV | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - AccessWire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVERV - AccessWire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
VERV DEADLINE: RLF, THE FIRST FILING FIRM, Encourages Verve - GlobeNewswire
How to Take Advantage of moves in (VERV) - Stock Traders Daily
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - AccessWire
State Street Corp's Strategic Acquisition in Verve Therapeutics - Yahoo Finance
2024-10-16 | Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics Inc (VERV) looking to reclaim success with recent performance - SETE News
Verve Therapeutics Insider Purchases Yet To Pay Off Regardless Of Recent Strength - Simply Wall St
ROSEN, A TOP RANKED LAW FIRM, Encourages Verve - GlobeNewswire
VERV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verve Therapeutics Inc Stock (VERV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
| Dorval Allison | Chief Financial Officer |
Nov 29 '23 |
Sale |
11.45 |
554 |
6,343 |
4,060 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):